Percutaneous hepatic perfusion improves response rates and progression-free survival in metastatic uveal melanoma
Liver perfusion shows better response rates for metastatic uveal melanoma
This meta-analysis of patients with metastatic uveal melanoma found that percutaneous hepatic perfusion (PHP) is associated with higher over…
A new analysis suggests liver perfusion may improve response and progression-free time for patients with a rare form of eye cancer.
Germline BAP1 variants are associated with aggressive clinical phenotypes in patients with uveal melanoma
Genetic variants linked to more aggressive eye cancer cases
This systematic review examines the clinical phenotype of uveal melanoma in patients harboring germline pathogenic or likely pathogenic BAP1…
A specific genetic marker, BAP1, is linked to earlier diagnoses and higher risks of spreading in certain types of eye cancer.
Tebentafusp provides modest survival benefit and manageable safety profile in metastatic uveal melanoma
Trial Shows Tebentafusp Offers Survival Benefit for Metastatic Uveal Melanoma
This systematic review and meta-analysis of 631 patients evaluates tebentafusp for metastatic uveal melanoma. The analysis found an overall …
Tebentafusp shows a modest survival benefit for patients with metastatic uveal melanoma, despite low response rates and manageable side effe…
Network meta-analysis compares therapies for liver metastatic uveal melanoma
Liver-directed therapy combined with ICIs leads for metastatic uveal melanoma survival
This systematic review and network meta-analysis synthesized evidence on therapeutic modalities for patients with liver metastatic uveal mel…
A network meta-analysis of 2,585 patients found liver-directed therapy combined with immune checkpoint inhibitors offered the best survival …
Combined tebentafusp and SBRT showed disease control in a patient with metastatic uveal melanoma
One Woman’s Rare Eye Cancer Spread. Then a New Combo Stopped It Cold
This case report describes a 39-year-old woman with localized uveal melanoma who developed liver and hilar adenopathy metastases.
This story shows how combining a new immune drug with targeted radiation may help the body fight cancer longer, even after it has spread.
Immunoembolization shows lower disease control than FOCUS trial in liver-dominant metastatic uveal melanoma
Eye Cancer in Liver: New Therapy Extends Life Even When Tumors Grow
This single-center retrospective analysis evaluated immunoembolization (IE) in 43 patients with liver-dominant metastatic uveal melanoma.
A new liver treatment for eye cancer patients may help them live longer, even if it does not shrink tumors as much as expected.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
Research across Melanoma
Related studies from across the Melanoma family.
Dual immune checkpoint inhibition provides durable intracranial progression-free survival in melanoma patients with brain metastases
Dual immune therapy shows promise for melanoma brain metastases
This meta-analysis of 3,518 patients with cutaneous or mucosal melanoma brain metastases indicates that dual immune checkpoint inhibition pr…
Combining two immune therapies may offer more durable results for patients with melanoma that has spread to the brain.
PD-1/PD-L1 inhibitors with SRS or FSRT achieve 87% one-year local control in brain metastases
Combining immunotherapy and radiation for brain metastases shows promise
This meta-analysis of 2587 patients with brain metastases evaluated the combination of PD-1/PD-L1 inhibitors with stereotactic radiosurgery …
A new analysis shows that combining specific immunotherapy drugs with radiation can help control brain tumors and manage side effects.
Genetic risk factors and a validated polygenic risk score identify melanoma risk loci
Genetic Risk Factors Linked to Melanoma Development Identified
This meta-analysis of 69,871 cases and 1,616,233 controls identifies 156 independent signals at 116 risk loci for cutaneous melanoma. The st…
Researchers identified over 150 genetic signals linked to melanoma, helping to better understand how genetics influence skin cancer risk.
CIC-Rearranged Intracranial Sarcoma: Local Control Achieved but Distant Spread Rapid Despite Multimodal Therapy
Rare brain tumor appears in patient with history of melanoma
This is a single-patient case report of a 36-year-old woman with a prior history of melanoma who developed an intracranial sarcoma. Gross to…
A 36-year-old woman with a history of melanoma developed a rare type of brain tumor called an intracranial sarcoma.
mRNA vaccines provide a clinically validated platform to induce durable anti-tumor immunity in solid tumors
mRNA Vaccines Show Potential for Treating Several Solid Tumors
This systematic review evaluates mRNA vaccines for melanoma, pancreatic cancer, and non-small cell lung cancer. The authors conclude that mR…
mRNA technology is being used to create cancer vaccines that may help patients with melanoma, pancreatic, and lung cancers by building lasti…
Artificial Intelligence Performance in Dermatoscopic Image Interpretation for Skin Cancer Diagnosis
AI Shows High Performance in Detecting Skin Cancer Images
A meta-analysis of 208 articles evaluates how AI compares to expert dermatoscopy in identifying melanoma and other common skin malignancies.
Artificial intelligence may improve the accuracy of diagnosing skin cancers like melanoma when analyzing specialized skin images.
Approximately 40% to 55% of patients with advanced melanoma exhibit primary resistance to PD-1 monotherapy
PD-1 Inhibitors Show Varying Resistance Rates in Advanced Melanoma
This systematic review examines resistance mechanisms to PD-1 and PD-L1 inhibitors in patients with advanced melanoma. It identifies primary…
New research identifies specific rates of initial and acquired resistance to PD-1 inhibitors in patients with advanced melanoma.
MITF E318K variant associated with significantly increased melanoma risk and high nevus burden
Specific gene variant linked to higher risk of multiple melanomas
This systematic review and meta-analysis of 8,606 melanoma patients and 17,953 controls identifies the MITF E318K variant as a moderate-pene…
A specific genetic variant called MITF E318K is linked to a significantly higher risk of developing multiple primary melanomas.
Melanoma Immunoediting Review Maps Elimination, Equilibrium, Escape and Drivers of Immunotherapy Resistance
Immune System Changes Drive Melanoma Growth and Treatment Resistance
This systematic review synthesizes the tumor immunoediting framework in melanoma, describing three sequential phases (elimination, equilibri…
New research highlights how the immune system's failure to eliminate melanoma cells leads to tumor growth and resistance to current therapie…
Medicinal plant extracts and phytochemicals show potential as multitargeted candidates for metastatic melanoma
Plant extracts show promise for treating advanced melanoma skin cancer
This narrative review explores the potential of medicinal plant extracts and isolated phytochemicals as multitargeted therapeutic candidates…
Certain medicinal plants and their natural compounds may offer a new way to target multiple pathways in advanced melanoma.
Self-administered ivermectin and fenbendazole in a patient with metastatic melanoma showed mixed radiographic and ctDNA responses
One man with melanoma tries antiparasitic drugs for his cancer
This case report describes a 74-year-old man with metastatic melanoma who self-administered ivermectin and fenbendazole. The patient experie…
A man with advanced melanoma saw a temporary drop in cancer markers after taking ivermectin and fenbendazole, but the results were mixed.
Encorafenib and Binimetinib Combination Therapy for Patients with BRAF Mutated Cutaneous Melanoma
Trial Shows Encorafenib and Binimetinib for Melanoma Patients
This trial evaluates the safety and efficacy of encorafenib and binimetinib in patients with resected stage IIB/IIC melanoma.
A clinical trial shows that a combination of encorafenib and binimetinib may improve recurrence-free survival for patients with specific mel…
Questions about Uveal Melanoma
Did a patient with uveal melanoma benefit from combined tebentafusp and SBRT?
Yes, a case report describes a patient with metastatic uveal melanoma who achieved durable disease control after adding SBRT to tebentafusp, with a partial response and 35 months of maintained control.
Full answer →What treatments are available for liver metastatic uveal melanoma patients?
Liver-directed therapy combined with immune checkpoint inhibitors appears most effective; tebentafusp is approved for HLA-A*02:01+ patients; other options include immunoembolization, SBRT, and clinical trials.
Full answer →How does immunoembolization compare to the FOCUS trial for uveal melanoma?
Immunoembolization shows lower disease control rates than the FOCUS trial for liver-dominant metastatic uveal melanoma, though tebentafusp combined with radiotherapy may offer durable control in specific cases.
Full answer →Can tebentafusp and SBRT control disease in uveal melanoma?
Yes, a case report shows tebentafusp plus SBRT controlled metastatic uveal melanoma for over 35 months, but more research is needed to confirm this approach.
Full answer →